Press Releases April 7, 2026 08:00 PM

Perma-Fix to Present at Gabelli Funds’ 12th Annual Waste & Environmental Services Symposium in New York City on April 9th

Perma-Fix Management to Present at Gabelli Funds' Waste & Environmental Services Symposium

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
PESI

Perma-Fix Environmental Services, Inc. announced that its CEO and CFO will present at the Gabelli Funds' 12th Annual Waste & Environmental Services Symposium in New York City. The event will focus on waste and environmental service industry trends, sustainability investing, and business fundamentals. The company offers nuclear and mixed waste management services, including treatment and decontamination across government and commercial sectors.

Perma-Fix to Present at Gabelli Funds’ 12th Annual Waste & Environmental Services Symposium in New York City on April 9th
PESI
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Perma-Fix executives are participating in a major industry symposium highlighting waste management and sustainability trends.
  • The company specializes in nuclear and mixed waste management for government and commercial clients.
  • Presentation and investor meetings may increase visibility among institutional investors focused on environmental services and waste management sectors.

ATLANTA, April 08, 2026 (GLOBE NEWSWIRE) -- Perma-Fix Environmental Services, Inc. (NASDAQ: PESI) (the “Company”) today announced that Mark Duff, Chief Executive Officer, and Ben Naccarato, Chief Financial Officer, will be presenting at Gabelli Funds’ 12th Annual Waste & Environmental Services Symposium, being held on Thursday, April 9th, 2026 in Midtown Manhattan, New York City. Mr. Duff and Mr. Naccarato are scheduled to present at 1:30 PM ET. Management will also be participating in one-on-one meetings with qualified investors throughout the conference.

The symposium will feature discussions with leading companies and organizations across the waste and environmental services ecosystems, with an emphasis on industry dynamics, current trends, and business fundamentals, as well as waste and sustainability investing and other relevant panels.

To register to attend the symposium, please follow this link. For those who cannot attend in person, the symposium will also be available via webcast.

About Perma-Fix Environmental Services
Perma-Fix Environmental Services, Inc. is a nuclear services company and leading provider of nuclear and mixed waste management services. The Company's nuclear waste services include management and treatment of radioactive and mixed waste for hospitals, research labs and institutions, federal agencies, including the U.S. Department of Energy (DOE), U.S. Department of War (DOW), and the commercial nuclear industry. The Company’s nuclear services group provides project management, waste management, environmental restoration, decontamination and decommissioning, demolition, and radiological protection, safety and industrial hygiene capability to our clients. The Company operates four nuclear waste treatment facilities and provides nuclear services at DOE, DOW, and commercial facilities nationwide.

Please visit us at http://www.perma-fix.com.

Contacts:
David K. Waldman-US Investor Relations
Crescendo Communications, LLC
(212) 671-1021

Herbert Strauss-European Investor Relations
[email protected]
+43 316 296 316


Risks

  • The nuclear and waste management industry is subject to regulatory changes which could impact operations.
  • Market volatility or shifts in government funding for nuclear services might affect company revenues.
  • Competition and technological changes in waste treatment solutions may pose challenges to maintaining market share.

More from Press Releases

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026 ROMA Green Finance Establishes Dedicated Artificial Intelligence and High-Performance Computing Infrastructure Investment Vertical Jun 12, 2026